HC Wainwright Estimates Rallybio’s Q2 Earnings (NASDAQ:RLYB)

Rallybio Co. (NASDAQ:RLYB) – Analysts at HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for Rallybio in a report issued on Wednesday, April 9th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.23) per share for the quarter, up from their previous estimate of ($0.29). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Rallybio’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for Rallybio’s Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.97) EPS.

Separately, Citizens Jmp downgraded shares of Rallybio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Rallybio currently has a consensus rating of “Hold” and a consensus target price of $9.33.

Rallybio Stock Performance

Rallybio stock opened at $0.25 on Friday. Rallybio has a twelve month low of $0.22 and a twelve month high of $2.77. The firm has a market cap of $10.42 million, a PE ratio of -0.16 and a beta of -1.35. The firm’s 50 day moving average price is $0.64 and its two-hundred day moving average price is $0.89.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Thursday, March 13th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.15 million.

Hedge Funds Weigh In On Rallybio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RLYB. Northeast Financial Consultants Inc grew its position in Rallybio by 336.5% in the fourth quarter. Northeast Financial Consultants Inc now owns 96,422 shares of the company’s stock worth $93,000 after acquiring an additional 74,334 shares in the last quarter. Allostery Investments LP bought a new stake in Rallybio in the fourth quarter worth $771,000. Almitas Capital LLC increased its position in Rallybio by 48.3% during the fourth quarter. Almitas Capital LLC now owns 1,298,119 shares of the company’s stock worth $1,246,000 after buying an additional 422,685 shares during the last quarter. Renaissance Technologies LLC increased its position in Rallybio by 9.3% during the fourth quarter. Renaissance Technologies LLC now owns 441,318 shares of the company’s stock worth $424,000 after buying an additional 37,618 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Rallybio by 11.4% during the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after buying an additional 24,980 shares in the last quarter. Institutional investors own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.